VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples. The findings also support the feasibility of early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The company said the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. Volition noted that this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
This advancement is significant because sepsis is a life-threatening condition that requires rapid diagnosis and treatment. Current diagnostic methods often rely on laboratory-based tests that can be time-consuming and are not readily available in all healthcare settings. A finger-prick test that can be performed at the point of care could dramatically reduce time to diagnosis and treatment, potentially improving patient outcomes. Moreover, the ability to detect nucleosomes—a marker of cell death and immune activation—in capillary blood opens the door to monitoring other diseases associated with NETosis, such as certain cancers.
Volition is a multi-national company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more details, the full press release can be accessed at https://ibn.fm/ioEmu. Further information about the company is available at www.Volition.com.
